Research and Markets: Investigation Report on China's Tacrolimus (FK506) Market 2010-2019

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/59m9j2/investigation)
has announced the addition of the “Investigation
Report on China’s Tacrolimus Market, 2010-2019”
report to their
offering.

Tacrolimus (FK506) is a macrolide lactone immunosuppressive drug
discovered from a soil sample that contained the bacterium Streptomyces
tsukubaensis in 1984 by Fujisawa Pharmaceutical Co., Ltd. Tacrolimus
acts like cyclosporine and its systemic use is mainly for the prevention
of allograft rejection and the treatment of immune disease. Different
from cyclosporine, it can penetrate through the epidermis barrier due to
its relatively small molecular mass. Therefore to avoid systemic adverse
reactions, it can be made into external preparation to treat various
immune inflammatory cutaneous disorders.

After entering China in 1999, tacrolimus developed fast with annual
sales rising from less than CNY 100 million in 2005 to CNY 688 million
in 2014 and CAGR reaching up to 24.7% during this period. Tacrolimus in
the Chinese market are in four formulations: injection, capsule, eye
drop and ointment, among which the sales value of capsules takes up over
90% of the sum in 2014. Tacrolimus is used for a variety of indications,
for example, capsules are mainly used to prevent graft rejection after
liver or kidney transplantation.

Tacrolimus in the Chinese market mainly comes from the following
companies: Fujisawa Pharmaceutical Co., Ltd (Ireland), Hisun, Zhejiang
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, Sichuan Med-Shine
Pharmaceutical Co., Ltd and Astellas Pharma Manufacturing Inc. among
which Fujisawa Pharmaceutical Co., Ltd (Ireland) has the largest market
share of 75.40% by sales value in 2014.

As the number of organ transplants and the number of cases of immune
disease increase, the sales value of tacrolimus in China is expected to
keep growing.

Key Topics Covered:

1 Related Concepts of Tacrolimus

2 Market Profile of Tacrolimus in China

3 Survey on Sales Value of Tacrolimus in China, 2010-2014

4 Survey on Sales Volume of Tacrolimus in China, 2010-2014

5 Survey on Market Share of Major Manufacturers of Tacrolimus in China,
2010-2014

6 Survey on Market Size of Dosage Forms of Tacrolimus in China, 2010-2014

7 Reference Retail Price of Tacrolimus in China in 2014

8 Major Manufacturers of Tacrolimus in the Chinese Market, 2010-2014

9 Market Outlook of Tacrolimus in China, 2014-2018

Companies Mentioned

– Astellas Pharma Manufacturing, Inc.

– Zhejiang Hisun Pharmaceutical Co., Ltd.

– Zhejiang Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd

– Sichuan Med-Shine Pharmaceutical Co., Ltd

– Yamanouchi Pharmaceutical Co., Ltd (Japan)

For more information visit http://www.researchandmarkets.com/research/59m9j2/investigation

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Powered by WPeMatico